Orchard Therapeutics plc ORTX

NAS: ORTX | ISIN: US68570P1012 23/01/2024

16,70 USD (+0,30%)

(+0,30%) 23/01/2024

Grafiek Orchard Therapeutics plc

Grafiek Orchard Therapeutics plc

1 dag1d 0,30%
1 week1w 0,00%
1 maand1m 0,00%
3 maanden3m 0,00%
6 maanden6m 5,03%
1 jaar1j 245,04%
5 jaar5j -11,41%

Orchard Therapeutics plc in het nieuws

Toon enkel gratis nieuws

26 oktober 2023 · Moore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law Firm · Persbericht

24 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHS, SLGC, ORTX, OLK · Persbericht

24 oktober 2023 · ALERT: The M&A Class Action Firm Continues Investigating the Merger - ORTX, SRT, CHS, ICPT · Persbericht

19 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHS, SLGC, ORTX · Persbericht

10 oktober 2023 · ALERT: The M&A Class Action Firm Continues Investigating the Merger - RPT, SP, ORTX, PNT · Persbericht

5 oktober 2023 · SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, ORTX, SUM · Persbericht

2 maart 2021 · Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments · Persbericht

9 februari 2021 · Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH) · Persbericht

5 februari 2021 · Orchard Therapeutics Announces $150 Million Strategic Financing · Persbericht

29 januari 2021 · Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer · Persbericht

Profiel Orchard Therapeutics plc

Gezondheidstechnologie

Werknemers: 207

Aandelen Orchard Therapeutics plc

Effecten: 2,28 miljoen

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe